Long Term Use Of Xalacom In Patients Glaucoma Or Ocular Hypertension

• Status: Completed
• Trial end date: 2015-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this Investigation is to evaluate the safety and efficacy of long-term treatment with Xalacom in medical practice. Also, occurrence of unknown and known adverse drug reactions (ADRs) in subjects treated with Xalacom will be monitored during the survey period, and whether an additional treatment outcome investigation and/or a post-marketing clinical study is required in the future will be determined.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Latanoprost; Maleic acid; Ophthalmic Solutions; Timolol

Criteria

Inclusion Criteria:

• Patients need to be administered Xalacom® in order to be enrolled in the surveillance.

Exclusion Criteria:

• Patients not administered Xalacom®.